Krystal Biotech Inc. Insider Trading

KRYS

Last 12 months

Insiders sold $105M and bought nothing on the open market.

87% of the selling was scheduled in advance under 10b5-1 plans. Director Dino A Rossi sold $8.23M on Aug 14, 33% of their stake, outside a plan. The last open-market buy by an executive or director was in Oct 2018.

Net open-market

−$105M

0 buys · 16 sales

Under a 10b5-1 plan

87%

of the value sold

Insiders who bought / sold

0 / 6

executives and directors

Last open-market buy

Oct 2018

Oct 18, 2018

Get an email when KRYS's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 4	Suma Krishnan President, R&D	Sold10b5-1 plan 13 parts	25,000	$359.32 average	$8.98M	1.6%	Form 4
Sep 4	Krish S Krishnan President and CEO	Sold10b5-1 plan 13 parts	25,000	$359.32 average	$8.98M	1.6%	Form 4
Aug 14	Dino A Rossi Director	SoldNo plan 8 parts	25,000	$329.12 average	$8.23M	33%	Form 4
Jun 25	John Charles Thomas EVP, General Counsel	Sold10b5-1 plan	1,000	$347.27	347K	100%	Form 4
Jun 4	Suma Krishnan President, R&D	Sold10b5-1 plan 11 parts	25,000	$308.12 average	$7.7M	1.6%	Form 4
Jun 4	Krish S Krishnan President and CEO	Sold10b5-1 plan 11 parts	25,000	$308.12 average	$7.7M	1.5%	Form 4
May 26	John Charles Thomas EVP, General Counsel	Sold10b5-1 plan	642	$302.03	194K	100%	Form 4
Mar 4	Suma Krishnan President, R&D	Sold10b5-1 plan 10 parts	25,000	$263.21 average	$6.58M	1.6%	Form 4
Mar 4	Krish S Krishnan President and CEO	Sold10b5-1 plan 10 parts	25,000	$263.17 average	$6.58M	1.5%	Form 4
Mar 2	Kathryn Romano Chief Accounting Officer	Sold10b5-1 plan	750	$267.60	201K	3.2%	Form 4
Feb 27	Daniel Janney Director	Sold10b5-1 plan 2 parts	11,803	$275.59 average	$3.25M	14%	Form 4
Feb 24 – 26	Daniel Janney Director	Sold10b5-1 plan 20 parts	60,161	$268.44 average	$16.1M	24%	Form 4
Feb 19	Dino A Rossi Director	SoldNo plan 2 parts	18,950	$261.41 average	$4.95M	19%	Form 4
Feb 9	Kathryn Romano Chief Accounting Officer	Sold10b5-1 plan 7 parts	12,500	$272.14 average	$3.4M	40%	Form 4
Dec 4, 2025	Suma Krishnan President, R&D	Sold10b5-1 plan 16 parts	50,000	$220.15 average	$11M	1.1%	Form 4
Dec 4, 2025	Krish S Krishnan President and CEO	Sold10b5-1 plan 16 parts	50,000	$220.15 average	$11M	1.6%	Form 4
Jul 14, 2025 – Jul 16, 2025	Suma Krishnan President, R&D	Sold10b5-1 plan 9 parts	35,873	$150.39 average	$5.39M	1.1%	Form 4
Jul 14, 2025 – Jul 16, 2025	Krish S Krishnan President and CEO	Sold10b5-1 plan 9 parts	35,873	$150.39 average	$5.39M	0.8%	Form 4
Jul 9, 2025 – Jul 10, 2025	Suma Krishnan President, R&D	Sold10b5-1 plan 6 parts	14,127	$150.27 average	$2.12M	0.5%	Form 4
Jul 9, 2025 – Jul 10, 2025	Krish S Krishnan President and CEO	Sold10b5-1 plan 6 parts	14,127	$150.27 average	$2.12M	0.5%	Form 4
Mar 13, 2025	Suma Krishnan President, R&D	Sold10b5-1 plan 10 parts	50,000	$177.79 average	$8.89M	1.6%	Form 4
Mar 13, 2025	Krish S Krishnan President and CEO	Sold10b5-1 plan 10 parts	50,000	$177.79 average	$8.89M	1.6%	Form 4
Feb 27, 2025	Kathryn Romano Chief Accounting Officer	Sold10b5-1 plan	750	$175.22	131K	3.7%	Form 4
Dec 13, 2024	Suma Krishnan President, R&D	Sold10b5-1 plan 17 parts	50,000	$164.80 average	$8.24M	1.6%	Form 4
Dec 13, 2024	Krish S Krishnan President and CEO	Sold10b5-1 plan 17 parts	50,000	$164.80 average	$8.24M	1.1%	Form 4

Sep 410b5-1 plan
Suma Krishnan
President, R&D · sold 25,000 at avg $359.32
$8.98M
1.6% of stake
Sep 410b5-1 plan
Krish S Krishnan
President and CEO · sold 25,000 at avg $359.32
$8.98M
1.6% of stake
Aug 14No plan
Dino A Rossi
Director · sold 25,000 at avg $329.12
$8.23M
33% of stake
Jun 2510b5-1 plan
John Charles Thomas
EVP, General Counsel · sold 1,000 at $347.27
347K
100% of stake
Jun 410b5-1 plan
Suma Krishnan
President, R&D · sold 25,000 at avg $308.12
$7.7M
1.6% of stake
Jun 410b5-1 plan
Krish S Krishnan
President and CEO · sold 25,000 at avg $308.12
$7.7M
1.5% of stake
May 2610b5-1 plan
John Charles Thomas
EVP, General Counsel · sold 642 at $302.03
194K
100% of stake
Mar 410b5-1 plan
Suma Krishnan
President, R&D · sold 25,000 at avg $263.21
$6.58M
1.6% of stake
Mar 410b5-1 plan
Krish S Krishnan
President and CEO · sold 25,000 at avg $263.17
$6.58M
1.5% of stake
Mar 210b5-1 plan
Kathryn Romano
Chief Accounting Officer · sold 750 at $267.60
201K
3.2% of stake
Feb 2710b5-1 plan
Daniel Janney
Director · sold 11,803 at avg $275.59
$3.25M
14% of stake
Feb 24 – 2610b5-1 plan
Daniel Janney
Director · sold 60,161 at avg $268.44
$16.1M
24% of stake
Feb 19No plan
Dino A Rossi
Director · sold 18,950 at avg $261.41
$4.95M
19% of stake
Feb 910b5-1 plan
Kathryn Romano
Chief Accounting Officer · sold 12,500 at avg $272.14
$3.4M
40% of stake
Dec 4, 202510b5-1 plan
Suma Krishnan
President, R&D · sold 50,000 at avg $220.15
$11M
1.1% of stake
Dec 4, 202510b5-1 plan
Krish S Krishnan
President and CEO · sold 50,000 at avg $220.15
$11M
1.6% of stake
Jul 14, 2025 – Jul 16, 202510b5-1 plan
Suma Krishnan
President, R&D · sold 35,873 at avg $150.39
$5.39M
1.1% of stake
Jul 14, 2025 – Jul 16, 202510b5-1 plan
Krish S Krishnan
President and CEO · sold 35,873 at avg $150.39
$5.39M
0.8% of stake
Jul 9, 2025 – Jul 10, 202510b5-1 plan
Suma Krishnan
President, R&D · sold 14,127 at avg $150.27
$2.12M
0.5% of stake
Jul 9, 2025 – Jul 10, 202510b5-1 plan
Krish S Krishnan
President and CEO · sold 14,127 at avg $150.27
$2.12M
0.5% of stake
Mar 13, 202510b5-1 plan
Suma Krishnan
President, R&D · sold 50,000 at avg $177.79
$8.89M
1.6% of stake
Mar 13, 202510b5-1 plan
Krish S Krishnan
President and CEO · sold 50,000 at avg $177.79
$8.89M
1.6% of stake
Feb 27, 202510b5-1 plan
Kathryn Romano
Chief Accounting Officer · sold 750 at $175.22
131K
3.7% of stake
Dec 13, 202410b5-1 plan
Suma Krishnan
President, R&D · sold 50,000 at avg $164.80
$8.24M
1.6% of stake
Dec 13, 202410b5-1 plan
Krish S Krishnan
President and CEO · sold 50,000 at avg $164.80
$8.24M
1.1% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch KRYS, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with KRYS

CompareIntrinsic value

TWSTTwist Bioscience Corporation

$142.58+1.63%40

IMCRImmunocore Holdings plc

$29.23-2.66%40

ADMAAdma Biologics Inc.

$10.48-5.67%82

NVAXNovavax Inc.

$10.65+10.02%10

MGTXMeiraGTx Holdings plc

$9.42-1.05%74

TARSTarsus Pharmaceuticals Inc.

$69.07-4.91%55

DNLIDenali Therapeutics Inc.

$20.81+6.97%10

IOVAIovance Biotherapeutics, Inc.

$8.70-1.47%10

Held by ETFs

KRYS is in 125 US ETFs. The largest of them, with KRYS's weight in each:

Spot a number that looks wrong? Check it in KRYS's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing KRYS

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.